GeneBioTech Co. Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.004x

GeneBioTech Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has a cash flow conversion efficiency ratio of -0.004x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-230.73 Million ≈ $-156.36K USD) by net assets (₩56.25 Billion ≈ $38.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of GeneBioTech Co. Ltd (2009–2025)

Cash flow conversion efficiency of GeneBioTech Co. Ltd from 2009 to 2025. This chart illustrates how GeneBioTech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GeneBioTech Co. Ltd (086060) stock price for real-time trading data and today's change.

GeneBioTech Co. Ltd Cash Flow Conversion Ratio Explained

GeneBioTech Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

GeneBioTech Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GeneBioTech Co. Ltd ranked by their cash flow conversion efficiency. Also see 086060 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Raval ACS Ltd TA:RVL	0.042x
ilShinbiobase Co. Ltd KQ:068330	0.006x
Kristal Kola ve Mesrubat Sanayi Ticaret AS IS:KRSTL	0.003x
Industrial Investment Trust Limited NSE:IITL	0.155x
Carbochim SA RO:CBC	N/A
Rand Capital Corp NASDAQ:RAND	0.009x
JSW Pacific TWO:5251	-0.002x
Semacom Integrated Tbk PT JK:SEMA	0.010x

Annual Cash Flow Conversion Efficiency for GeneBioTech Co. Ltd (2009–2025)

The table below shows the annual cash flow conversion efficiency of GeneBioTech Co. Ltd from 2009 to 2025. Review 086060 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩55.00 Billion ≈ $37.27 Million	₩7.61 Billion ≈ $5.16 Million	0.138x	+1621.35%
2024-12-31	₩50.97 Billion ≈ $34.54 Million	₩-463.87 Million ≈ $-314.36K	-0.009x	-105.97%
2023-12-31	₩48.30 Billion ≈ $32.74 Million	₩7.37 Billion ≈ $4.99 Million	0.153x	+289.60%
2022-12-31	₩45.73 Billion ≈ $30.99 Million	₩-3.68 Billion ≈ $-2.49 Million	-0.080x	-24.45%
2021-12-31	₩43.95 Billion ≈ $29.78 Million	₩-2.84 Billion ≈ $-1.93 Million	-0.065x	-216.88%
2020-12-31	₩45.04 Billion ≈ $30.52 Million	₩2.49 Billion ≈ $1.69 Million	0.055x	+196.80%
2019-12-31	₩46.93 Billion ≈ $31.80 Million	₩-2.68 Billion ≈ $-1.82 Million	-0.057x	-146.02%
2018-12-31	₩47.96 Billion ≈ $32.50 Million	₩5.96 Billion ≈ $4.04 Million	0.124x	+343.93%
2017-12-31	₩40.49 Billion ≈ $27.44 Million	₩1.13 Billion ≈ $767.40K	0.028x	-79.46%
2016-12-31	₩39.02 Billion ≈ $26.44 Million	₩5.31 Billion ≈ $3.60 Million	0.136x	+50.66%
2015-12-31	₩28.84 Billion ≈ $19.54 Million	₩2.61 Billion ≈ $1.77 Million	0.090x	-1.78%
2014-12-31	₩23.42 Billion ≈ $15.87 Million	₩2.15 Billion ≈ $1.46 Million	0.092x	-10.63%
2013-12-31	₩23.10 Billion ≈ $15.65 Million	₩2.38 Billion ≈ $1.61 Million	0.103x	-20.67%
2011-12-31	₩19.48 Billion ≈ $13.20 Million	₩2.53 Billion ≈ $1.71 Million	0.130x	+104.69%
2010-12-31	₩18.38 Billion ≈ $12.45 Million	₩1.17 Billion ≈ $789.56K	0.063x	-57.24%
2009-12-31	₩18.08 Billion ≈ $12.25 Million	₩2.68 Billion ≈ $1.82 Million	0.148x	--

About GeneBioTech Co. Ltd

KQ:086060 Korea Pharmaceuticals

Market Cap

$28.28 Million

₩41.73 Billion KRW

Market Cap Rank

#23809 Global

#1655 in Korea

Share Price

₩4985.00

Change (1 day)

-0.89%

52-Week Range

₩3600.00 - ₩5230.00

All Time High

₩10031.60